Compare Moody's Corporation (MCO) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Zoetis Inc — how do they compare? Moody's Corporation trades at $464.23 (market cap $79.44B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Moody's Corporation is far larger — about 2.6× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 132 Days and Zoetis Inc for 70 Days on average.
| MCO | ZTS | |
|---|---|---|
Market Cap | $79.44B | $30.20B |
Volume | 526,684 | 6,175,327 |
Sector | Financials | Health |
52-Week High | $539.61 | $147.53 |
52-Week Low | $412.23 | $69.09 |
Typical Hold Time | 132 Days | 70 Days |
Enterprise Value | $85.46B | $37.76B |
Dividend Yield | 0.9% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCO trades at $464.23, up 3.25% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 34.25% net margins and 80.15% ROE. Recent developments include a minority stake acquisition in PhilRatings and continued leadership in risk analytics, supported by 56% analyst buy ratings and a $536.40 consensus target.
Outlook remains positive given consistent revenue growth and expanding profitability, though technical resistance near $464 and high valuation multiples pose near-term risks. Long-term investors may find value in MCO's market position and dividend yield, but should monitor debt levels and macroeconomic sensitivity.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
